Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Training network for tracking and controlling therapeutic immune cells in cancer

Descrizione del progetto

Tracciamento delle cellule immunitarie durante l’immunoterapia

L’immunoterapia del cancro può aiutare il sistema immunitario a riconoscere e attaccare le cellule tumorali. I trattamenti comprendono anticorpi monoclonali, citochine, trasferimento adottivo di cellule immunitarie o altri approcci immuno-modulanti. Nonostante le promesse, i meccanismi alla base di queste terapie rimangono poco conosciuti, in particolare il modo in cui le cellule immunitarie si riposizionano e interagiscono dopo il trattamento. Con il sostegno del programma di azioni Marie Skłodowska-Curie, il progetto T-RAFIC mira ad aumentare le conoscenze sul traffico di cellule immunitarie durante la terapia, in particolare durante le combinazioni di immunoterapia. Il consorzio si avvarrà di innovazioni tecnologiche per consentire un tracciamento senza precedenti delle cellule immunitarie e contribuire, in ultima analisi, a migliorare l’efficacia dei trattamenti in questo campo emergente dell’oncologia e non solo.

Obiettivo

Cancer immunotherapies have been established in a growing number of clinical indications and the pace of development is massively accelerating. Currently over 6.000 clinical trials are investigating immune-related treatments in oncology especially in combinations. It includes both adoptive cellular therapies and immune modulating treatments like immune check point blockade. In contrast, the understanding of how such therapies mediate their mode of action is still mostly poorly understood. In particular, the role of distribution and relocation of immune cells after therapeutic interventions remains unknown. This is surprising, as immune cell interactions are a hallmark of therapeutic immune responses. T-RAFIC will enhance understanding of immune cell trafficking under therapeutic influence. It will open new paths and avenues to treatments, boost their efficacy and help prioritizing the plethora of immune therapeutic combinations. In the past, detailed analysis of cellular distributions was facing technical barriers. Advances in technologies, now permit tracking and visualization of cells in vitro and in vivo at an unprecedented resolution, allowing for the first time studies on immune cells under therapeutic influence. This emerging field of research has enormous potential and key importance for next generation of researchers in oncology and beyond. However, experts in this field are missing and this threats European research, development and medicine. Therefore, T-RAFIC joins forces of 13 academic and three industrial partners from nine European countries to conduct an innovative and interdisciplinary approach combining cell imaging with bioinformatics, cell engineering and clinician expertise. The network bundles recognised expertise in cancer immunotherapies, empowering European research and innovation and ensuring a sustainable cooperation in science and training.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Parole chiave

Coordinatore

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Contribution nette de l'UE
€ 781 617,60
Indirizzo
GESCHWISTER SCHOLL PLATZ 1
80539 MUNCHEN
Germania

Mostra sulla mappa

Regione
Bayern Oberbayern München, Kreisfreie Stadt
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Partecipanti (10)

Partner (14)